In the past week, DYN stock has gone up by 9.88%, with a monthly decline of -41.91% and a quarterly plunge of -48.75%. The volatility ratio for the week is 6.62%, and the volatility levels for the last 30 days are 7.76% for Dyne Therapeutics Inc The simple moving average for the last 20 days is -6.34% for DYN’s stock, with a simple moving average of -52.98% for the last 200 days.
Is It Worth Investing in Dyne Therapeutics Inc (NASDAQ: DYN) Right Now?
The 36-month beta value for DYN is at 1.11. Analysts have varying views on the stock, with 7 analysts rating it as a “buy,” 4 rating it as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for DYN is 76.64M, and currently, shorts hold a 12.27% of that float. The average trading volume for DYN on February 05, 2025 was 1.64M shares.
DYN) stock’s latest price update
The stock of Dyne Therapeutics Inc (NASDAQ: DYN) has increased by 6.63 when compared to last closing price of 13.87.Despite this, the company has seen a gain of 9.88% in its stock price over the last five trading days. globenewswire.com reported 2025-02-03 that WALTHAM, Mass., Feb. 03, 2025 (GLOBE NEWSWIRE) — Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage neuromuscular disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced that management is scheduled to present during a virtual fireside chat at the Oppenheimer 35th Annual Healthcare Life Sciences Conference on Tuesday, February 11, 2025 at 4:00 p.m. ET.
Analysts’ Opinion of DYN
Many brokerage firms have already submitted their reports for DYN stocks, with Robert W. Baird repeating the rating for DYN by listing it as a “Outperform.” The predicted price for DYN in the upcoming period, according to Robert W. Baird is $46 based on the research report published on December 13, 2024 of the previous year 2024.
RBC Capital Mkts, on the other hand, stated in their research note that they expect to see DYN reach a price target of $45. The rating they have provided for DYN stocks is “Outperform” according to the report published on November 26th, 2024.
JP Morgan gave a rating of “Neutral” to DYN, setting the target price at $35 in the report published on October 24th of the previous year.
DYN Trading at -34.22% from the 50-Day Moving Average
After a stumble in the market that brought DYN to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -68.83% of loss for the given period.
Volatility was left at 7.76%, however, over the last 30 days, the volatility rate increased by 6.62%, as shares sank -40.27% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -50.17% lower at present.
During the last 5 trading sessions, DYN rose by +9.88%, which changed the moving average for the period of 200-days by -40.41% in comparison to the 20-day moving average, which settled at $15.79. In addition, Dyne Therapeutics Inc saw -37.22% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at DYN starting from Beskrovnaya Oxana, who sale 2,334 shares at the price of $28.12 back on Dec 11 ’24. After this action, Beskrovnaya Oxana now owns 201,685 shares of Dyne Therapeutics Inc, valued at $65,632 using the latest closing price.
Scalzo Richard William, the SVP, Head of Finance & Admin. of Dyne Therapeutics Inc, sale 1,455 shares at $28.12 during a trade that took place back on Dec 11 ’24, which means that Scalzo Richard William is holding 127,078 shares at $40,915 based on the most recent closing price.
Stock Fundamentals for DYN
Current profitability levels for the company are sitting at:
- -83.02 for the present operating margin
- 0.64 for the gross margin
The net margin for Dyne Therapeutics Inc stands at -77.75. The total capital return value is set at -0.43. Equity return is now at value -68.69, with -60.47 for asset returns.
Based on Dyne Therapeutics Inc (DYN), the company’s capital structure generated 0.03 points at debt to capital in total, while cash flow to debt ratio is standing at -9.78. The debt to equity ratio resting at 0.04. The interest coverage ratio of the stock is -186.18.
Currently, EBITDA for the company is -233.48 million with net debt to EBITDA at 1.62. When we switch over and look at the enterprise to sales, we see a ratio of 263.41. The liquidity ratio also appears to be rather interesting for investors as it stands at 17.02.
Conclusion
In conclusion, Dyne Therapeutics Inc (DYN) has had a bad performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
